Dermapharm Holding SE : Preliminary 2023 results broadly in line with expectations – 2024 guidance stronger than it seems at first glance
>2023 EBITDA at the upper end of the guidance – slightly below our estimates - Dermapharm released preliminary revenue for 2023 of € 1.135m (+11%), 2% above our and the consensus’ estimates. Adj. EBITDA came in at € 310.2m (-14%) slightly below our estimates (€ 314m) but above the cons. (€ 308m). The 2023 guidance was € 300-310m. The EBITDA decline of 14% reflects the end of the BioNTech collaboration for the production of the Covid vaccine, which stopped at the end o...Dermapharm Holding SE. Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.